Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 23;131(18):2060–2064. doi: 10.1182/blood-2017-12-820605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society of Hematology

PMC Copyright notice

Figure 1. — Characteristics of tumors with DLBCL morphology that have MYC rearrangement with or without BCL2 and/or BCL6 rearrangements. (A) Percentages of tumors that harbor MYC rearrangement in the presence or absence of concomitant BCL2 and/or BCL6 rearrangements. Analyses involving COO are based on the 1098 tumors in the cohort in which COO was determined using the Lymph2Cx gene expression-based assay. (B) COO and IHC results for tumors with MYC rearrangement. Each column represents an individual tumor, with the exception of the total cohort in the bottom left corner, included to show percentages of the characteristics in the 1228 patients. P values are for Fisher’s exact tests comparing the frequency of the characteristic in the group vs the total cohort. Additional comparisons were: *P: HGBL-DH/TH with BCL2 rearrangement group vs the total cohort; **P: all HGBL-DH/TH vs the total cohort; ***P: MYC rearrangement group vs the total cohort.